Elsubrutinib

DRUG4 trials

Sponsors

AbbVie

Conditions

Rheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE)

Phase 2

A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis

CompletedNCT03682705

AbbVieRheumatoid Arthritis (RA)

Start: 2018-10-08End: 2020-03-26Updated: 2021-05-03

A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib

TerminatedNCT03823378

AbbVieRheumatoid Arthritis (RA)

Start: 2019-05-13End: 2020-09-09Updated: 2021-09-16

A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)

CompletedNCT03978520

AbbVieSystemic Lupus Erythematosus (SLE)

Start: 2019-07-25End: 2022-07-14Updated: 2023-07-21

A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State

CompletedNCT04451772

AbbVieSystemic Lupus Erythematosus (SLE)

Start: 2020-07-27End: 2024-01-03Updated: 2025-01-14

Related Papers

Efficacy and safety of upadacitinib as monotherapy or combined with elsubrutinib for the treatment of systemic lupus erythematosus: results through 104 weeks in a long-term extension study

RMD Open2025-07-013 citations

Improvements in BILAG Musculoskeletal and Mucocutaneous Domains at Week 48 in a Phase 2 Double-Blind Placebo-Controlled Trial of ABBV-599 (Elsubrutinib + Upadacitinib Combination) and Upadacitinib Monotherapy for Treatment of Moderately to Severely Active Systemic Lupus Erythematosus

The Journal of Rheumatology2025-07-01

MODULAR GENE EXPRESSION CHANGES IN THE SLEEK PHASE 2 STUDY OF UPADACITINIB AND ABBV-599 IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

The Journal of Rheumatology2025-05-20

EFFICACY AND SAFETY OF ELSUBRUTINIB AND UPADACITINIB COMBINATION AND UPADACITINIB MONOTHERAPY FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS THROUGH 104 WEEKS

The Journal of Rheumatology2025-05-20

Monitoramento do Horizonte Tecnológico (MHT) de Inibidores de Janus Quinase (JAKi) para o Tratamento de Lúpus Eritematoso Sistêmico (LES)

Epidemiologia e Serviços de Saúde2025-01-01

Efficacy and Safety of Upadacitinib or Elsubrutinib Alone or in Combination for Patients With Systemic Lupus Erythematosus: A Phase 2 Randomized Controlled Trial

Arthritis & Rheumatology2024-06-2538 citations

Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial.

2022-04-279 citations